Title |
Big Data in Pharmaceutical R&D: Creating a Sustainable R&D Engine
|
---|---|
Published in |
Pharmaceutical Medicine, March 2015
|
DOI | 10.1007/s40290-015-0090-x |
Pubmed ID | |
Authors |
Peter Tormay |
Abstract |
Over the last 20 years, productivity in the pharmaceutical industry has been diminishing because of constantly increasing costs while output has overall been stagnant. Despite many efforts, productivity remains a challenge within the industry. At the same time, healthcare providers quite rightly require better value for money and clear evidence that new drugs are better than the current standard of care, making a complex situation even more complex. With the implementation of 'Big Data' initiatives trying to integrate data from disparate data sources and disciplines that are available in life science, the industry has identified a new frontier that might provide the insights needed to turn the ship around and allow the industry to return to sustainable growth. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 40% |
Spain | 2 | 40% |
Belgium | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
United States | 1 | <1% |
Canada | 1 | <1% |
Unknown | 103 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 24 | 23% |
Researcher | 16 | 15% |
Student > Bachelor | 13 | 12% |
Student > Ph. D. Student | 11 | 10% |
Student > Doctoral Student | 5 | 5% |
Other | 14 | 13% |
Unknown | 23 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Computer Science | 16 | 15% |
Business, Management and Accounting | 11 | 10% |
Engineering | 10 | 9% |
Medicine and Dentistry | 10 | 9% |
Biochemistry, Genetics and Molecular Biology | 9 | 8% |
Other | 21 | 20% |
Unknown | 29 | 27% |